Have a personal or library account? Click to login
A Clinical Approach of Lupus Nephritis Associated with Catastrophic Antiphospholipid - Antibody Syndrome - Review and Case Report Cover

A Clinical Approach of Lupus Nephritis Associated with Catastrophic Antiphospholipid - Antibody Syndrome - Review and Case Report

Open Access
|Jan 2023

References

  1. 1.. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 4(2):295–306.10.1111/j.1538-7836.2006.01753.x16420554
  2. 2. Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol (2009) 36(2–3):131–40.10.1007/s12016-008-8112-z19048414
  3. 3. Abu-Shakra M, Urowitz MB, Gladman DD, Ritchie S. The significance of anticardiolipin antibodies in patients with lupus nephritis. Lupus (1996) 5(1):70–3.10.1177/0961203396005001138646230
  4. 4. Bhandari S, Harnden P, Brownjohn AM, Turney JH. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. QJM (1998) 91(6):401–9.10.1093/qjmed/91.6.4019709458
  5. 5. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis (2004) 43(1):28–36.10.1053/j.ajkd.2003.09.01114712424
  6. 6. Natejumnong C, Ruangkanchanasetr P, Aimpun P, Supaporn T. Significance of antiphospholipid antibodies in lupus nephritis. J Med Assoc Thai (2006) 89(Suppl 2): S121–8.
  7. 7. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int (1991) 39(6):1225–31.10.1038/ki.1991.1551716712
  8. 8. Parodis I, Arnaud L, Gerhardsson J, Zickert A, Sundelin B, Malmström V, et al. Antiphospholipid antibodies in lupus nephritis. PLoS One (2016) 11(6): e0158076.10.1371/journal.pone.0158076491900727336701
  9. 9. Mehrani T, Petri M. IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus. J Rheumatol (2011) 38(3):450–3.10.3899/jrheum.10065021123325
  10. 10. Appel GB, Pirani CL, D’Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol (1994) 4(8):1499–515.10.1681/ASN.V4814998025223
  11. 11. Farrugia E, Torres VE, Gastineau D, Michet CJ, Holley KE. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis (1992) 20(5):463–7110.1016/S0272-6386(12)70258-51442758
  12. 12. Hughson MD, Nadasdy T, McCarty GA, Sholer C, Min KW, Silva F. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis (1992) 20(2):150–8.10.1016/S0272-6386(12)80543-9
  13. 13. Bridoux F, Vrtovsnik F, Noël C, Saunier P, Mougenot B, Lemaitre V, et al. Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant (1998) 13(2):298–304.10.1093/oxfordjournals.ndt.a0278229509438
  14. 14. Zheng H, Chen Y, Ao W, Shen Y, Chen XW, Dai M, et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res Ther (2009) 11(3): R93.10.1186/ar2736271414919545416
  15. 15. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther (2013) 15(1): R12.10.1186/ar4142367279223320601
  16. 16. Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int (2013) 83(4):715–23.10.1038/ki.2012.40923302713
  17. 17. Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol (2008) 35:1983–8.
  18. 18. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum. 2003 Feb;48(2):300–312.10.1002/art.1073912571837
  19. 19. Hernando Monserrat, González Concepción, Sánchez Angel, Guevara Paloma, Navajo José Alejandro, Papisch Wolfgang, González-Buitrago José Manuel. Clinical evaluation of a new automated anti-dsDNA fluorescent immunoassay. Clin Chem Lab Med. 2002 Oct;40(10):1056–1060.10.1515/CCLM.2002.18512476949
  20. 20. 20.Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost. 2012 Jun;38(4):333-8.10.1055/s-0032-130471822618528
  21. 21. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J: Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 59: 2156–2163, 200110.1046/j.1523-1755.2001.00730.x11380817
DOI: https://doi.org/10.2478/inmed-2022-0231 | Journal eISSN: 1220-5818 | Journal ISSN: 1220-5818
Language: English
Page range: 77 - 87
Published on: Jan 14, 2023
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2023 Marilena Stoian, Gabriel Scarlat, Silviu Șeitan, Bianca Procopiescu, published by Romanian Society of Internal Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.